tbuckley/cabot-search huggingface dataset:
AB0761 Efficacy of per-Cutaneous Ultrasound Guided Drainage of Degenerative Meniscal Cysts in Knee Osteoarthritis Patients
Authors: M. Mortada, N. Ezzeldin, M. Hammad
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Meniscal cysts presented in about 4% of patients with knee osteoarthritis [1]. Meniscal cysts may result in pain and disability in the knee. Ultrasound may be used for therapeutic aspiration of the cyst [2]. <h3>Objectives</h3> To evaluate the efficacy of ultrasound guided percutaneous drainage of symptomatic meniscal cysts in patients with knee osteoarthritis. <h3>Methods</h3> Ultrasound guided percutaneous drainage of symptomatic meniscal cysts were performed in 38 patients with Knee osteoarthritis in the period between January 2013 and December 2015. Thirty cysts were related to the medial meniscus and 8 cysts were related to the lateral meniscus. Cysts were injected with local anaesthetic before completion of procedure. All 38 patients were subsequently followed up one month and 6 months after the aspiration with the primary outcome measures were the Western Ontario and McMaster Universities OA Index total pain score WOMAC (a Likert scale), patient global assessment (PGA) questionnaires and musculoskeletal ultrasonography assessment. <h3>Results</h3> In every case the procedure was well tolerated. Complete aspiration of the cyst were performed in 15 patients (39.5%) and partial aspiration were performed in 23 patients (60.5%). Before aspiration US meniscal cyst measurements 29.5±9.2 mm * 13.6±4.5 mm. At the end of the 1st month, there was a reduction of 50% in the WOMAC pain score. 89.4% (34 patients) felt that their knee pain had improved compared to baseline. At this time point just US meniscal cyst measurements 19.5±5.2 mm * 11.6±4.1 mm. At the end of the 6th month post aspiration, there was a reduction in the WOMAC pain score of 30%. At this time point just 78.9% (30 patients) felt that their knee pain had improved compared to baseline. At this time point just US meniscal cyst measurements 25.5±6.2 mm * 13.6±3.6 mm. Patient outcomes did not significantly correlate with any meniscal cyst characteristic. Complete aspiration was associated with better outcomes. <h3>Conclusions</h3> Ultrasound-guided percutaneous aspiration of degenerative meniscal cysts is a well-tolerated, simple, and safe procedure for patients with knee osteoarthritis. <h3>References</h3> Campbell SE, Sanders TG, Morrison WB. MR imaging of meniscal cysts: incidence, location, and clinical significance. AJR Am J Roentgenol. 2001;177 (2): 409–13. P. J. MacMahon, D. D. Brennan, D. Duke, S. Forde, and S. J. Eustace, "Ultrasound-guided percutaneous drainage of meniscal cysts: preliminary clinical experience," Clinical Radiology, vol. 62, no. 7, pp. 683–687, 2007. <h3>Disclosure of Interest</h3> None declared
SAT0189 Characterization of Extracellular Histidyl-TRNA Synthetase in Myositis
Authors: C. Fernandes Cerqueira, A. Sohrabian, I. Albrecht, A. Notarnicola, E. Ossipova, J. Lengqvist, M. Fati, G.J. Pruijn, J. Grunewald, J. Rönnelid, I.E. Lundberg, P.-J. Jakobsson
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Histidyl-transfer RNA synthetase (HisRS) is a major autoantigen in myositis with lung involvement<sup>1–4</sup>. Simultaneous presence of anti-HisRS and anti-Ro52 antibodies has been demonstrated in patients with myositis<sup>5–7</sup>. <h3>Objectives</h3> We investigated the presence of HisRS in the extracellular compartments plasma, sera and bronchoalveolar lavage fluid (BAL). In addition, the occurrence of anti-HisRS antibody isotypes as well as other auto-reactivities was evaluated in BAL and sera from patients with myositis. <h3>Methods</h3> HisRS was measured in sera, plasma and BAL from myositis (anti-HisRS antibody positive, anti-Jo1+ and negative, anti-Jo1-), sarcoidosis, rheumatoid arthritis (RA) patients and healthy controls (HC) by dot-blot, western-blot, immunoprecipitation and mass spectrometry. The presence in BAL and sera of anti-Jo1 isotypes and other ANA-associated autoantibodies was analysed by ELISA and addressable laser bead immunoassay. <h3>Results</h3> HisRS was detected in sera, plasma and BAL of patients with myositis, sarcoidosis and RA and in HC. HisRS systemic levels were elevated in anti-Jo1+ myositis (14 out of 20 sera) compared to anti-Jo1- myositis (10/18), sarcoidosis (0/8) and RA (3/15) patients, and HC (5/23). In BAL, significant levels of HisRS were detected in 6/8 HC and 5/8 sarcoidosis, compared to 4/8 myositis (2 anti-Jo1+ and 2 anti-Jo1-). Our results demonstrated the presence of a factor in BAL with high binding capacity for HisRS and HisRS complexed with anti-HisRS-N-terminal antibody. C1q-binding immune complexes (IC) containing HisRS were not the binding factor. However, anti-Jo1 isotypes as well as anti-Ro52 IgG were identified in both BAL (5/8 patients were positive for anti-Jo1 IgG, 3/8 for anti-Jo1 IgA, 3/8 for anti-Jo1 IgM and 4/8 for anti-Ro52 IgG) and sera (5/8 for anti-Jo1 IgG, 3/8 for anti-Jo1 IgA, 4/8 for anti-Jo1 IgM and 3/8 for anti-Ro52 IgG) from patients with myositis. Furthermore, a positive correlation between the presence of anti-Jo1 IgG and anti-Ro52 IgG in BAL was identified (r<sup>2</sup>=0,881; p=0,007). <h3>Conclusions</h3> HisRS was detected both in blood and BAL fluid. The identification of extracellular HisRS, anti-Jo1 isotypes and anti-Ro52 in myositis BAL may provide additional clues for the development of autoimmunity in the lungs. <h3>References</h3> Bernstein RM., et al. Br Med J (Clin Res Ed). 1984 Jul 21;289(6438):151–2; Marguerie C., et al. Q J Med. 1990 Oct;77(282):1019–38; Hervier B., et al. Eur Respir J. 2013 Nov;42(5):1271–82; Hamaguchi Y., et al. PLoS One. 2013;8(4):e60442; La Corte R., et al. Autoimmunity. 2006 May;39(3):249–53; Brouwer R., et al. Ann Rheum Dis. 2001 Feb;60(2):116–23; Rutjes SA., et al. Clin Exp Immunol. 1997 Jul;109(1):32–40. <h3>Disclosure of Interest</h3> None declared
The Things We Have Lost
Authors: Jennifer A. Best
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Tissue-specific programming of memory CD8 T cell subsets impacts protection against lethal respiratory virus infection
Authors: Georges Abboud, Pritesh Desai, Farhad Dastmalchi, Jessica Stanfield, Vikas Tahiliani, Tarun E. Hutchinson, Shahram Salek-Ardakani
Journal: The Journal of Experimental Medicine (2016)

How tissue-specific anatomical distribution and phenotypic specialization are linked to protective efficacy of memory T cells against reinfection is unclear. Here, we show that lung environmental cues program recently recruited central-like memory cells with migratory potentials for their tissue-specific functions during lethal respiratory virus infection. After entering the lung, some central-like cells retain their original CD27hiCXCR3hi phenotype, enabling them to localize near the infected bronchiolar epithelium and airway lumen to function as the first line of defense against pathogen encounter. Others, in response to local cytokine triggers, undergo a secondary program of differentiation that leads to the loss of CXCR3, migration arrest, and clustering within peribronchoarterial areas and in interalveolar septa. Here, the immune system adapts its response to prevent systemic viral dissemination and mortality. These results reveal the striking and unexpected spatial organization of central- versus effector-like memory cells within the lung and how cooperation between these two subsets contributes to host defense.
P0545 : Targeting viral DNA with CRISPR/Cas9 robustly suppresses hepatitis B virus
Authors: None Shlomai, V. Ramanan, D.B. Cox, R.E. Schwartz, E. Michailidis, A. Bhatta, F. Zhang, S.N. Bhatia, C.M. Rice
Journal: Journal of Hepatology (2015)
HLA Ligandome Analysis of Acute Myeloid Leukemia (AML) Revealed Novel Tumor-Associated Antigens for Immunotherapy.
Authors: Juliane Sarah Stickel, Claudia Berlin, Daniel Johannes Kowalewski, Heiko Schuster, Lothar Kanz, Helmut R Salih, Hans-Georg Rammensee, Stefan Stevanovic
Journal: Blood (2012)
SAT0417 Evolution of MRI Inflammation and Structural Lesions on Serial Scans over 5 Years in Patients with Ankylosing Spondylitis Treated with Tumor-Necrosis-Factor-Alpha Inhibitors: Table 1.
Authors: S.J. Pedersen, U. Weber, R. Said-Nahal, I.J. Sørensen, A.G. Loft, N. Tvede, G. Kollerup, L. Juul, G. Thamsborg, O.R. Madsen, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Only few studies have investigated evolution of MRI inflammation (infl.) and structural lesions by serial MRI and radiography (CX) in patients with ankylosing spondylitis (AS). <h3>Objectives</h3> To investigate evolution of infl. and structural lesions over 5 years on MRI and CX during treatment with TNFα inhibitors (TNFα-I) with multiple serial examinations. <h3>Methods</h3> The study population comprised 34 patients with AS followed for 5 years after initiation of TNFα-I. MRIs of the sacroiliac joints (SIJs) and lower spine (Th9-S1) and spinal CXs were performed 7 and 4 times, respectively. UW and RSN evaluated the MRIs and CXs, respectively, in known time sequence. MRIs were evaluated according to the SPARCC sacroiliac (SIJ) and Spine Infl. Index and Structural Scores (SSS) (1). The Canada-Denmark MRI definitions of infl., fat (2), erosion and new bone formation (3,4) were transformed into scores. The CXs were scored according to the modified Stoke AS Spine Score (mSASSS). <h3>Results</h3> MRI infl., compared to baseline, decreased significantly in SIJ and spine from week 22 and onwards, while SIJ erosion decreased significantly from week 46 (see table). Conversely, the SIJ and spinal MRI fat and SIJ ankylosis scores increased significantly from week 22. Only minor changes for SIJ backfill and spine erosion score were observed. These findings indicate that reduction of infl. during TNF-I is followed by structural progression. During the 5 years of TNF-I, mSASSS and the structural MRI spine score SASSS had, compared to baseline, increased significantly from year 1 and 2, respectively, and onwards. <h3>Conclusions</h3> Shortly after initiation of TNF-I spine and SIJ MRI infl. decreased and structural scores changed indicating new bone formation. Thereafter the MRI scores remained unchanged. In constrast, mSASSS continuously increased. <h3>References</h3> Maksymowych et al. J Rheum 2014; Pedersen et al. Arthritis Res Ther 2014; Lambert et al. J Rheum 2009; Østergaard et al. J Rheum 2009 <h3>Disclosure of Interest</h3> None declared
SAT0378 Modification of Structural Lesions on Magnetic Resonance Imaging by Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Authors: W.P. Maksymowych, S. Wichuk, M. Dougados, H. Jones, A. Szumski, L. Marshall, J.F. Bukowski, R.G. Lambert
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC) sacroiliac joint (SIJ) score (SSS) assesses the degree of fat metaplasia (new tissue growth after resolution of inflammation), erosion, backfill (new tissue growth at erosion site), and ankylosis observed on MRI in the SIJ. <h3>Objectives</h3> To evaluate the impact on these lesions at 12 wks in patients with non-radiographic axial SpA receiving PBO or etanercept (ETN) in the EMBARK study (ClinicalTrials.gov: NCT01258738). <h3>Methods</h3> Patients had axial SpA per ASAS criteria without meeting modified NY radiographic criteria; BASDAI score ≥4; symptoms for &gt;3 months and &lt;5 yrs; and had failed ≥2 NSAIDs. Patients were randomized to double-blind ETN 50 mg/wk or PBO for 12 wks, then received open-label ETN. Structural lesions were scored using the SPARCC SSS method on T1-weighted spin echo (T1WSE) MRI. Two readers independently scored baseline (BL) and 12-wk T1WSE MRI scans, blinded to patients, time point, and inflammation scores assessed by short tau inversion recovery MRI scans. Readers9 mean scores were used. <h3>Results</h3> Mean (SD) age was 32 (7.8) yrs, 60.5% were male, duration of disease symptoms was 2.4 (1.8) yrs, 71.6% were human leukocyte antigen B27+, and 80.9% had sacroiliitis on MRI (modified intent-to-treat [mITT] population, N=215). MRI scans from 185 patients (ETN, n=88; PBO, n=97) with BL and 12-wk scans were reviewed. At BL, there were no significant differences in mean SPARCC SSS scores between ETN and PBO (table). From BL to 12 wks, change in mean SPARCC SSS score was significantly greater for ETN than PBO for erosion (-0.57 vs -0.08, respectively, <i>p</i>=0.009) and backfill (0.36 vs 0.06, <i>p</i>=0.021), table. A treatment difference was also present for the subgroup of patients with MRI inflammation (figure). <h3>Conclusions</h3> Treatment with ETN was associated with significantly greater reduction in erosion and increase in backfill at 12 wks vs. PBO, consistent with a very early reparative response to anti-TNF therapy. The impact of this new data on disease progression in SpA should be studied further. <h3>Disclosure of Interest</h3> W. Maksymowych Grant/research support from: AbbVie, Consultant for: AbbVie, Amgen, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceutica, L.P, Pfizer, UCB, S. Wichuk: None declared, M. Dougados Grant/research support from: Pfizer, AbbVie, UCB, Merck, Eli Lilly, Sanofi, Consultant for: Pfizer, AbbVie, UCB, Merck, Eli Lilly, Sanofi, H. Jones Shareholder of: Pfizer, Employee of: Pfizer, A. Szumski Employee of: InVentiv Health, L. Marshall Shareholder of: Pfizer, Employee of: Pfizer, J. Bukowski Shareholder of: Pfizer, Employee of: Pfizer, R. Lambert Consultant for: Bioclinica
In Vitro and In Vivo Inhibition of P-Glycoprotein (ABCB1) by a Novel Non-Substrate Compound: HG-829
Authors: Gisela Caceres, Robert W Robey, Lubomir Sokol, Kathy Rocha McGraw, William J Fulp, Justine Clark, Nicholas J Lawrence, Said Sebti, Susan E. Bates, Alan F. List
Journal: Blood (2010)
Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML
Authors: Sarah Cooley, Michael R. Verneris, Julie Curtsinger, David McKenna, Daniel J. Weisdorf, Bruce R. Blazar, Thomas A Waldmann, Jeffrey S. Miller
Journal: Blood (2012)
NIMG-61QUANTITATIVE MRI MORPHOLOGIC CHARACTERISTICS AND QUANTITATIVE HISTOLOGIC PROFILES IN SURGICALLY PROVEN RADIATION NECROSIS VERSUS RECURRENT BRAIN TUMOR
Authors: Lisa Rogers, Leo Wolansky, Chaitra Badve, Curt Tatsuoka, Kate Clancy, Mark Cohen
Journal: Neuro-Oncology (2015)

BACKGROUND: Distinguishing radiation necrosis (RTN) from recurrent brain tumor (RBT) by standard MRI morphology poses significant challenges. In addition, histologic features associated with RTN and RBT have not been quantified, leading to diagnostic imprecision at lesion resection. We quantitated morphologic MRI characteristics and histologic features in RTN and RBT in irradiated brain tumor patients undergoing lesion resection of imaging progression. METHODS: Retrospective review of irradiated brain tumor patients with imaging progression identified at lesion resection to be predominant RTN (>80% radiation necrosis) or predominant RBT ( >80% active tumor). Two neuroradiologists blinded to diagnosis quantitated (0,   75%) presurgical MRI features. A profile of histologic findings was similarly scored by one neuropathologist blinded to diagnosis. RESULTS: Study group includes 54 cases for MRI review (30 RBT, 20 RTN) and 38 for histology review (20 RBT and 18 RTN). In a multivariate model of quantitated imaging features, probabilities that RTN and RBT can be estimated in glioma patients are 71% for RBT, 65% for RTN via ROC analysis. T1 hyperintensity, necrosis, spreading wavefront and Swiss cheese/soap bubble appearance are moderately correlated with RTN. In brain metastasis, 89% of RTN and 70% of RBT cases are correctly classified. In pathology specimens, significant differences in severity of zonal geographic necrosis in glioma (p = 0.002) and metastasis (p = 0.012) and severity of vascular hyalinization in glioma (p= 0.44) were identified. Fibrinoid and coagulative necrosis and vessel wall thickening were not significantly different in RTN versus RBT. CONCLUSIONS: Quantitative assessment of morphologic MRI abnormalities can assist in distinguishing RTN from RBT, especially in brain metastasis. Quantitative assessment of histologic features identified features significantly correlated with RTN versus RBT. A larger sample size is needed to confirm these findings and is ongoing. Grant support: UL1 RR024989 from NCRR/NIH
A Comparison of Acute and Delayed Infection Rates among Patients with Indolent Lymphoid Malignancies Receiving Fludarabine(F) and Cyclophosphamide(C) with or without Rituximab(R).
Authors: Constantine S. Tam, John Francis Seymour, Michael Brown, Philip Campbell, John D. Scarlett, Craig Underhill, David Ritchie, Rodney Bond, Andrew Grigg
Journal: Blood (2004)
Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma.
Authors: Antonella Caivano, Francesco La Rocca, Alessandra Favole, Sonia Carturan, Enrico Bracco, Oreste Villani, Giuseppe Pietrantuono, Ilaria Laurenzana, Luciana De Luca, Annalisa Morano, Vittorio Simeon, Stefania Trino, Simona Berardi, Antonio Basile, Angelo Vacca, Pellegrino Musto, Daniela Cilloni
Journal: Blood (2012)
FRI0649-HPR Innovation in Health Care – Laboratory Validity and Reliability of A New Sensor Developed To Measure Cervical Rotation
Authors: C. Fongen, N. Østerås, F.R. Andersen, V. Berre, A.T. Tveter, K.B. Hagen
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> For patients with axial spondyloarthritis (axSpA) it is recommended to monitor spinal mobility regularly. Cervical rotation (CR) is usually measured with goniometer or myrinometer, but might give imprecise results. Technological innovation provides opportunities to develop and improve measurement methods for use in clinical practice. <h3>Objectives</h3> To evaluate validity and reliability of a sensor developed to measure rotation around the vertical axis in a laboratory setting. <h3>Methods</h3> A sensor was developed by engineers in close collaboration with health professionals and patients with axSpA. It was tested in a laboratory setting and the data collected was compared with Cybex 6000 simulation data as gold standard. The sensor was mounted to the cybex with a bracket in six different positions, 1) straight up 2) straight down 3) up, tilted 30°around the frontal axis 4) down, tilted 30°around the frontal axis 5) up, tilted 30°around the frontal axis, 20° around the sagittal axis 6) down, tilted 30°around the frontal axis, 20° around the sagittal axis. Reference angles were set at approximately 10, 30, 60, 90 and 120 degrees. From a centre position the sensor was moved from left to right (one cycle) by manual force at the speed allowed (60°/second) until stop brackets were reached. Criterion validity and reliability for single measures and for the mean of three trials (left, right or cycle) was evaluated with two ways mixed interclass correlation coefficient<sub>agreement</sub> (ICC). Limits of agreement (LoA) (Bland and Altman method), and smallest detectable change<sub>agreement</sub> (SDC<sub>95%</sub>) with 95%CI were calculated to evaluate the measurement error of the sensor. <h3>Results</h3> A total number of 261 cycles were performed. The ICC values were excellent for all measurement (ICC: 1.0; 95% CI 1.0, 1.0). One cycle of movement showed lower measure error (LoA) compared to single measures (left or right) (table 1). The measurement error was further improved by using the mean of 3 cycles (figure 1). The SDC<sub>95</sub> was 0.87 for one cycle and 0.80 for the mean of three cycles. <h3>Conclusions</h3> The sensor showed excellent criterion validity and reliability for rotation around the vertical axis in the range of motion from 10 to 120 degrees, especially for cycles and mean of 3 cycles. When assessing a single cycle or the average of three cycles, a change of 1 degree is needed for real change beyond measurement error. Our findings justify proceeding with further evaluations of the sensor in patients with axSpA. <h3>Disclosure of Interest</h3> None declared
Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification
Authors: Ingmar Blümcke, Eleonora Aronica, Albert Becker, David Capper, Roland Coras, Mrinalini Honavar, Thomas S. Jacques, Katja Kobow, Hajime Miyata, Angelika Mühlebner, José Pimentel, Figen Söylemezoğlu, Maria Thom
Journal: Nature Reviews Neurology (2016)